KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS.

Mehul Patel, Jonathan Marshall, Fernando J Martinez, Alec Mushunje, Karin Bowen, Martin Jenkins

Respir Med 250 108499

PMID41237914
PMCID-
DOI10.1016/j.rmed.2025.108499
发表日期2025-11-14
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Frequent productive cough (FPC) is associated with increased exacerbation risk in chronic obstructive pulmonary disease (COPD). These post hoc analyses examined COPD exacerbations in participants without a recent exacerbation history by baseline FPC status (defined as COPD Assessment Test [CAT] subscores ≥2 for both cough and sputum) and for budesonide/glycopyrrolate/formoterol fumarate (BGF) versus dual therapies. METHODS: KRONOS (NCT02497001) was a 24-week, double-blind, parallel-group, multi-center, Phase III, randomized study in symptomatic people with moderate-to-very severe COPD; COPD exacerbation in the preceding 12 months was not required. Participants were randomized 2:2:1:1 to receive BGF 320/18/9.6 μg, glycopyrrolate/formoterol fumarate (GFF) 18/9.6 μg, budesonide/formoterol fumarate (BFF) 320/9.6 μg via metered-dose inhaler, or open-label budesonide/formoterol fumarate 400/12 μg via dry-powder inhaler (BUD/FORM), as two inhalations twice-daily. RESULTS: Of 1411 participants in the modified intent-to-treat population without a recent COPD exacerbation history, 965 (68.4 %) had baseline FPC. Moderate/severe exacerbation rates were higher in those with versus without FPC (BGF, 0.47 vs 0.29; BFF, 0.45 vs 0.37; BUD/FORM, 0.67 vs 0.14), except for GFF (0.79 vs 0.83). BGF was associated with reduced moderate/severe exacerbation rates among those with FPC (41 % reduction) and without FPC (65 % reduction) at baseline versus GFF, with similar findings observed in moderate COPD (FPC: 37 % reduction; without FPC, 72 % reduction). CONCLUSIONS: Among participants without an exacerbation history in the prior 12 months, FPC identified those at higher exacerbation risk. Further, BGF was associated with lower COPD exacerbation rates versus GFF, including numerically lower among those with moderate COPD and regardless of FPC status. CLINICAL TRIAL REGISTRATION: NCT02497001.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。